We’re supporting the NHS and social care by providing guidance about COVID-19 and backing efforts to get promising diagnostics and treatments to patients quickly. We update our guidance when new evidence comes out so that the health and care system can find current, reliable advice as it continues to respond to the pandemic.
Having prioritised therapeutically critical topics earlier in the pandemic, we’ve begun to publish planned guidance again now that the health and care system is starting to return to normal arrangements.Everything we've said relevant to COVID-19Register for updates
Managing symptoms and complications
- Acute kidney injury in hospital - NG175
- Acute myocardial injury - NG171
- Antibiotics for pneumonia in adults in hospital - NG173
- Critical care in adults - NG159
- Managing suspected or confirmed pneumonia in adults in the community - NG165
- Managing symptoms (including at the end of life) in the community - NG163.
Managing conditions that increase risk
- Children and young people who are immunocompromised - NG174
- Chronic kidney disease - NG176
- Community-based care of patients with chronic obstructive pulmonary disease (COPD) - NG168
- Cystic fibrosis - NG170
- Dermatological conditions treated with drugs affecting the immune response - NG169
- Gastrointestinal and liver conditions treated with drugs affecting the immune response - NG172
- Interstitial lung disease - NG177
- Rheumatological autoimmune, inflammatory and metabolic bone disorders - NG167
- Severe asthma - NG166.
Rapid evidence summaries
These summaries cover:
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES23.
- Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis - ES26
- Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 - ES24
- Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 - ES25
- Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 - ES27
- Vitamin D for COVID-19 - ES28.
Medtech innovation briefings
These innovative technologies have been identified as being potentially useful during the COVID-19 pandemic:
- CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic - MIB219
- Cytokine adsorption devices for treating respiratory failure in people with COVID-19 - MIB217
- Lifelight First for monitoring vital signs - MIB213
- myCOPD for self-management of chronic obstructive pulmonary disease - MIB214.
Clinical knowledge summaries
These are concise, accessible summaries of current evidence for primary care professionals.
We've added some information about coronavirus - COVID-19 which is largely based on guidance from Public Health England.
Developing rapid guidelines
Rapid guidelines are developed with NHS England and NHS Improvement and a cross-speciality clinical group, supported by the specialist societies and royal colleges. They are developed quickly using a different approach to normal. We’re keeping them under review.
More information about other topics we're looking at and how they are prioritised is available.
Developing rapid evidence summaries
These look at whether certain medicines may increase the severity or length of COVID-19 illness.
We're working with the Medicines and Healthcare products Regulatory Agency. Together we'll facilitate rapid review of information and advice on the safety and efficacy of treatments for COVID-19.
This framework helps manufacturers gather the best possible data and evidence. Making sure developers are working to the same standards supports investment into good quality trials and studies. It could also speed up the availability of accurate tests for use in the NHS.
You can read our guide, developed with the NIHR, on clinical evidence generation for COVID-19 medicines. We can also provide free scientific advice for researchers developing novel diagnostics or therapeutics for COVID-19.
We've developed a guide on assessing the quality of wider sources of data and evidence in our COVID-19 guidance. It's for internal guidance developers and external collaborators.
For our COVID-19 products we have waived our normal licensing requirements for international reuse or reproduction of our content.
Email us with any feedback about our rapid guidelines and evidence summaries.